Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced that it is working with Amazon Web Services (AWS) to redefine the future of lab processes in the life sciences industry.
The life science and pharmaceutical industries have long struggled with outdated laboratory processes that hinder efficiency and increase costs. Lab technicians, lab associates, and medical specialists often find themselves performing tasks outside of their expertise due to the fragmentation of laboratory operations across various platforms. This lack of cohesion not only results in inefficiencies but also extends the time required to bring new drugs and products to market, subsequently increasing research and development expenses.
Recognizing these challenges, Wipro began working with AWS to create the Lab of the Future. This innovative solution addresses the root issues that have plagued the industry, offering a comprehensive, cloud-based platform that streamlines laboratory processes and enhances collaboration among stakeholders.
“Our vision with launching Lab of the Future is to deliver holistic lab performance powered by generative AI, advanced analytics, and a consultative business first approach,” said Philippe Dintrans, Senior Vice President & Global Head of Domain & Consulting at Wipro Consulting.
Among the key challenges facing the Life Sciences industry today are decreasing ROI for R&D (R&D returns fell to 1.8% in 2019, down from 10% in 20101), increasing cost of bringing new drugs to the market, and the significant amount of time spent on data management, which takes 45% of data scientists’ time, according to recent surveys.2
By introducing the Lab of the Future, Wipro and AWS aim to empower the life sciences industry with a modern, efficient, and collaborative laboratory solution that has the potential to significantly reduce costs and accelerate the development of life-saving drugs and products.
“Wipro has enhanced offerings for clients across the life sciences value chain and our latest Lab innovation with AWS further illustrates our commitment to helping our clients improve business outcomes and enable cost efficiency,” said Srini Rajamani, Senior Vice President & Sector Head – Consumer and Life Sciences at Wipro.
The Lab of the Future offers a range of modules and solutions designed to transform laboratory operations. Among them:
- Lab as a Service: This module focuses on creating and optimizing labs from the ground up. It includes performance tracking and risk assessment through the Wipro Total Intelligence user dashboard.
- Safety Notifications: This module can deliver notifications to lab staff to alert hazardous events such as chemical spills and fires, providing immediate action plans in accordance with standard operating procedures (SOPs) and Material Safety Data Sheets (MSDS).
- Inventory Management: This module tracks and manages lab equipment stock, calibration cycles, utilization, wear and tear, and Internet of Things (IoT) updates, ensuring efficient inventory management.
- Scientific Information Platform: Provides instant access to scientific reference information with the help of virtual subject matter experts.
- Biomarker Hub: This module enables personalized medicine through DNA sequencing and the integration of digital biomarker data.
- E-Lab Notebook: Automatically records lab notes during experiments, reducing the burden of manual documentation.
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading technology services and consulting company focused on building innovative solutions that address clients’ most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With nearly 245,000 employees and business partners across 65 countries, we deliver on the promise of helping our clients, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry.
Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
1 Among 12 leading large-cap biopharma companies, R&D returns fell to 1.8% in 2019—down from 10% in 2010
https://www.us.jll.com/en/views/real-estate-as-reagent-how-the-right-life-sciences-space-can-drive-innovation
2 https://www.datanami.com/2020/07/06/data-prep-still-dominates-data-scientists-time-survey-finds/
View source version on businesswire.com: https://www.businesswire.com/news/home/20231130989584/en/
